tremelimumab
tremelimumab (intravenous infusion at 10 mg/kg) , every 4 weeks for seven doses as induction treatment, followed by maintenance dosing every 12 weeks
placebo
tremelimumab matching placebo, every 4 weeks for seven doses as induction treatment, followed by maintenance dosing every 12 weeks
cross over was permitted for placebo arm in accordance with protocol eligibility criteria.No dose reductions were allowed
malignant mesothelioma (mMS) - 2nd line (L2)
Patients with any histological subtypes of malignant mesothelioma (epithelioid,sarcomatoid, and biphasic) were allowed to participate.
double-blind
105 study centres across 19 countries
A hierarchical gate-keeping strategy was applied in this study, OS then secondary endpoint
Tremelimumab did not significantly prolong overall survival compared with placebo in patients with previously treated malignant mesothelioma.